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Abstract: Reliable markers for both renal cell carcinoma (RCC) and transitional cell carcinoma of the bladder (TCC) are 
lacking. 
During tumor progression and invasion components of extracellular matrix (ECM) are degraded and parts of these dif-
ferent components are detectable in plasma. Cellular ﬁ  bronectin (cFN) represents a well characterized ECM protein. In 
contrast to ﬁ  bronectin in plasma produced by hepatocytes (FN) cFN has a total extra domain sequence and occurs in much 
smaller amounts in the circulation. The aim of our study was to evaluate cFN as a marker and to determine its possible role 
in clinical staging of TCC and RCC.
Blood samples were collected from 30 patients before they underwent transurethral resection of the bladder because of 
newly diagnosed TCC. Additionally samples were collected from 69 patients with RCC before therapy. Sixty patients with 
non-malignant urological disorders were recruited as control group. Determination of cFN in plasma was performed by 
using a highly sensitive time-resolved ﬂ  uorescence immunoassay (TRFIA).
The control group had median cFN plasma levels of 437 ng/ml. Patients suffering from TCC or RCC showed signiﬁ  -
cantly higher cFN levels. In patients with muscle invasive TCC signiﬁ  cant higher cFN levels (p < 0.05) could be demon-
strated compared to non-muscle invasive TCC. Similar results were found in RCC with signiﬁ  cant elevated cFN levels in 
metastatic RCC (p < 0.005) compared to localized stage of disease. No differences were found concerning tumor grading 
in both malignancies. 
In the face of signiﬁ  cant elevated cFN levels in TCC and RCC our data underline the important role of cFN. For future 
investigations the elevated cFN levels in locally progressed and metastastic disease, indicating a clinically useful tool for 
preoperative staging and postoperative monitoring, are of high interest.
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Introduction
Beside prostate cancer (PCA) transitional cell carcinoma of the bladder (TCC) and renal cell carcinoma 
(RCC) are the most frequent urological malignancies with rising incidence (Motzer and Russo, 2000; 
Huland H, 2006). For early detection, adequate stage adjusted therapy and risk adapted follow-up tumor 
markers would be a helpful clinical tool. A reliable tumor marker is only available for PCA since the 
introduction of prostate speciﬁ  c antigen. Various blood, urine and molecular markers have been described 
in TCC and RCC. But only for screening and monitoring patients with non-muscle invasive TCC FDA-
approved urinary markers, like BTA- and NMP22 tests, are available (Giannopoulos et al. 2001; Boman H, 
et al. 2002). However, most of these potential markers have not reached clinical relevance due to low 
sensitivities, speciﬁ  cities or high costs (Zhao et al. 2005; Malats et al. 2005; Andreadis et al. 2005; 
Hegele et al. 2002; von Knobloch et al. 2002; Kashyap et al. 2005). 
In TCC 75% of patients are initially presented with a superﬁ  cial, 20% with muscle invasive and 5% 
with metastatic stage of disease (Heney, 1992). After primary treatment TCC recurs in 70% within a 
short time period and unfortunately about 20% will progress from superﬁ  cial to advanced/metastatic 
stage of disease (Amling, 2001). In RCC we found a similar clinical dilemma. Twenty to thirty percent 
of primary localized disease will relapse despite adequate therapy and 30% are presented initially in a 
metastasized stage of disease with poor prognosis (Giberti et al. 1997; Whelan, 2003). In the face of 
these data it is of signiﬁ  cant clinical interest to identify reliable markers for early detection and moni-
toring TCC and RCC after initial therapy. Biomarker Insights 2007: 2 2
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Formation of metastases and local progression 
of tumors presuppose degradation of extracellular 
matrix (ECM) components. These essential steps 
are possible by hydrolytic enzymes of the tumor 
itself and induction by the tumor in the stromal 
cells (Danen, 2005; von Bredow et al. 1995). Prod-
ucts of this various ECM components degradation 
are released in the circulation and determination 
of these components can be helpful for early detec-
tion of several malignancies (Risteli and Risteli, 
1995). Fibronectin (FN), a 440-KD glycoprotein, 
represents a well characterized ECM protein 
playing an important role in the inhibition of 
cellular attachment and tumor spread. The mecha-
nism of FN action is mediated by speciﬁ  c receptors 
and growth factors (Danen, 2005; Hynes and 
Yamada, 1982). The main detectable fraction of 
FN in blood is synthesized by hepatocytes. In 
contrast cellular ﬁ  bronectin (cFN) is found in much 
smaller amounts in the circulation. Cellular FN 
contains a speciﬁ  c extradomain sequence origi-
nating by differential splicing of the FN precursor 
mRNA. However, up to now the function of cFN 
is not clearly known (Warawdekar et al. 2006; 
Akiyama et al. 1995). Few studies described the 
potential role of cFN in different malignancies 
(Ylatupa et al. 1995; Haglund et al. 1997; 
Torbenson et al. 2002; Warawdekar et al. 2006). 
For example in hepatocellular carcinoma an over-
expression of fibronectin protein was found 
(Torbenson et al. 2002). Elevated plasma levels 
were detected in patients suffering gastrointestinal 
and head/neck cancer (Warawdekar et al. 2006). 
In non-malignant diseases particularly in throm-
bosis, hemostasis, vascular disease and platelet 
function the deﬁ  nitive role of ﬁ  bronectin is still 
unclear (Cho and Mosher, 2006; Mosher, 2006; 
Orem et al. 2002).
Recent studies in TCC and RCC indicating a 
potential role of cFN in these malignancies (Kirkali 
et al. 2001; Sanchez-Carbayo et al. 2000;Brenner 
et al. 2000). So further evaluation of cFN plasma 
levels, based on our ﬁ  rst ﬁ  ndings (Hegele et al. 
2004; Hegele et al. 2002), is a consequent step to 
prove the clinical relevance in different stages of 
these malignancies and close this diagnostic gap.
Material and Methods
To evaluate the value of cFN in different stages of 
TCC and RCC blood samples were collected in the 
morning before any therapy. Physical examination, 
chest X-ray, abdominal sonography and CT/MRT 
scan, where appropriate, were used for clinical 
staging. Patients showing other malignancies in 
medical history were excluded.
Blood samples were collected consecutively 
from 30 patients (13 women, 17 men, mean age 
64 years) with newly diagnosed TCC without 
evidence of metastases before they underwent 
transurethral tumor resection over a time period of 
4 months (March 2005–June 2005).
Additionally blood samples were collected from 
45 consecutive patients (19 women, 26 men, mean 
age 69 years) with localized RCC before operative 
therapy over a time period of 10 months (September 
2004–June 2005). Twenty-four patients (13 
women, 11 men, mean age 63 years) with meta-
static RCC before planned immunochemotherapy 
were also recruited in this time period. Out of the 
metastatic group 11 patients were initially presented 
with metastases and 13 developed metastatic 
disease during follow up after primary curative 
chirurgical intervention. 
Sixty patients (30 women, 30 men, mean age 
61 years) with benign urological disorders (for 
example stone disease, urinary tract infection, 
benign prostatic hyperplasia, urinary inconti-
nence) and without malignancies in their medical 
history were consecutively recruited as control 
group.
Blood samples were collected in tubes coated 
with the potassium salt of ethylene diamine tetra-
acetic acid (EDTA, Sarstedt, Germany) and 
processed for plasma within 3 hours. After 
centrifugation (2000 rpm, 10min, 4
oC) and 
removal of supernatant plasma, the samples were 
stored at –70
oC. 
cFN was determined using a highly sensitive 
time-resolved ﬂ  uorescence immunoassay (TRFIA). 
This sandwich-type assay, which is speciﬁ  c for the 
cellular form of FN, is based on a cFN-speciﬁ  c 
murine monoclonal antibody (provided by BIOHIT 
PLC, Finnland) immobilized on standard enzyme-
linked immunosorbent assay microwells. Standards 
and samples were assessed in duplicate. A poly-
clonal FN-speciﬁ  c antiserum (rabbit) obtained 
from Sigma-Aldrich (Germany), was used as the 
secondary antibody. For the ﬁ  nal detection step a 
modiﬁ  ed biotin-streptavidin method with measure-
ment of an europium-positive chelator was used 
(Kropf and Gressner, 1995; Kropf et al. 1991).
The assay has a linear measuring range from 
12–3000 ng/ml and a detection limit of 4.0 ng/ml. Biomarker Insights 2007: 2 3
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Figure 1. cFN plasma levels according to the different malignancy groups.
* (p < 0.05) and ** (p < 0.005) vs. controls.
Measurement of samples was always performed 
by the same person (B.K.).
The pathohistologic examination of the main 
tumor specimens was performed by the Institute 
of Pathology, Philipps-University Marburg, 
according to the classiﬁ  cation of the International 
Union against Cancer 2002 (Wittekind et al. 2003). 
At least two experienced, board certiﬁ  ed patholo-
gist reviewed the specimens. 
Statistical analysis was performed using the non 
parametric Mann-Whitney U test to compare the 
results of the malignancy groups with controls. The 
Kruskal-Wallis non-parametric ANOVA test was 
used to calculate the differences between the 
different groups and subgroups concerning TNM 
classiﬁ  cation and nuclear grading (SPSS® soft-
ware). A p-value <0.05 was accepted as statistically 
signiﬁ  cant.
Results
The intra-assay variance was evaluated by 20-fold 
determination of one sample. The coefﬁ  cient of 
variation was 4.9%. The inter-assay variance was 
determined on 7 different days. The coefﬁ  cient of 
variation was 6.9%.
The histological type of RCC was clear cell 
carcinoma in all patients. All patients undergoing 
TUR-B showed transitional cell carcinoma in 
histological examination.
The control group showed median cFN plasma 
levels of 437 ng/ml (mean 652 ng/ml, range 
181–2512 ng/ml, SD ± 374 ng/ml). 
The TCC group showed significant higher 
median cFN plasma levels with 521 ng/ml (p < 0.02, 
mean 836 ng/ml, range 274–3145 ng/ml, SD ± 
447 ng/ml) compared to controls (Fig. 1). Subdi-
viding the TCC group according to the UICC Biomarker Insights 2007: 2 4
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Figure 2. Signiﬁ  cant higher levels of cFN in patients with muscle invasive TCC compared to non-muscle invasive TCC (p < 0.05).
TNM-system of 2002 [24] in non-muscle invasive 
(< pT2, n = 20) and muscle invasive (> = pT2, n = 10) 
disease signiﬁ  cant higher levels of plasma cFN (p 
< 0.05) could be detected in the muscle invasive 
group (median 1126 ng/ml, mean 1847 ng/ml, SD 
± 664 ng/ml) compared to the non-muscle invasive 
group (median 379 ng/ml, mean 643 ng/ml, SD ± 
267 ng/ml, Fig. 2). 
Both the localized and metastatic RCC group 
showed signiﬁ  cant higher levels of plasma cFN 
(p < 0.005) compared to controls (Fig. 1). 
According to tumor stage in patients with localized 
RCC no signiﬁ  cant differences were noted. Patients 
with metastatic RCC (median 1764 ng/ml, mean 
5727 ng/ml, 478–8967 ng/ml, SD ± 3403 ng/ml) 
showed signiﬁ  cant higher levels of cFN (p < 0.01) 
compared to localized RCC (median 765 ng/ml, 
mean 1139 ng/ml, range 282–5271 ng/ml, SD ± 
962 ng/ml, Fig. 3). The location and number of 
metastases showed no signiﬁ  cant inﬂ  uence of cFN 
plasma levels. 
In both malignancy groups there were no 
signiﬁ  cant differences concerning nuclear grading 
(p > 0.5 respectively).
Discussion
The goal of the present study was to evaluate the 
clinicial suitability of cFN for diagnosis and moni-
toring of patients suffering TCC and RCC. Until 
now for both urological malignancies no markers 
are present in clinical routine. Cellular FN, repre-
senting a multifunctional glycoprotein, seems to 
play an important role in local tumor progression 
and migration (Hynes and Yamada, 1982). In 
contrast to total FN, cFN is found in much smaller 
amounts in circulation and is not mainly synthesized Biomarker Insights 2007: 2 5
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Figure 3. Signiﬁ  cant elevated cFN levels in patients with metastatic RCC compared to localized stage of disease (p < 0.01).
by hepatocytes. Most available antibodies are 
directed against both forms. So discrimination 
between FN synthesized by hepatozytes and cFN is 
not possible and interpretation of the results is difﬁ  -
cult when using conventional available immunoas-
says. The applied time-resolved ﬂ  uorescence immu-
noassay has been thoroughly tested (Kropf and 
Gressner, 1995; Kropf et al. 1991). Using a mono-
clonal speciﬁ  c antibody it is possible to detect cFN 
without disturbing FN interference. The time-
resolved ﬂ  uorescence method is not easily available 
so in future the development of an assay based on 
photometrical detection is planned.
In TCC an insoluble matrix form of FN was 
found along the urothelian tissue, but studies 
revealed diverse results of FN expression in 
bladder cancer tissue (Kirkali et al. 2001; Sanchez-
Carbayo, 2000; Cheng et al. 1988; Zhang et al. 
2004; Fleischmann et al. 1993). FN seems to play 
a major role in TCC and the response to intra-
vesical immunotherapy with Bacillus Calmette-
Guérin (BCG) after tumor resection. But this role 
is completely unclear as reﬂ  ected in contradictory 
ﬁ  ndings concerning FN urine levels (Zhang et al. 
2004; Fleischmann et al. 1993; Danisman et al. 
2000). A possible explanation maybe the different 
detection methodologies used, their incompara-
bility and patient dependent urine production with 
different consecutive FN concentrations. So detec-
tion in blood might be an additional tool and offer 
the chance to get more reliable and conclusive 
data. 
We found signiﬁ  cant elevated cFN levels in 
patients with TCC compared to controls pointing 
at the valuable but unclear role in TCC. The rela-
tionship between cFN and tumor progression is 
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reﬂ  ected in signiﬁ  cant higher levels in patients with 
muscle invasive stage compared to non-muscle 
invasive stages. These ﬁ  ndings are of interest for 
clinical routine. Eventually cFN plasma levels can 
play a role as supplementing tool beside histopa-
thology and for monitoring during follow-up. A 
long term study is ongoing to clarify if initial 
elevated cFN plasma levels in non-muscle invasive 
TCC are accompanied with an earlier recurrence 
and/or progression of TCC. Additionally further 
investigations have to be performed to determine 
cFN plasma levels after successful primary therapy 
and during follow-up.
In RCC FN also seems to play an important role. 
Murata and co-workers showed an inﬂ  uence of FN 
on migration of different RCC cell lines in culture. 
SN12C-2 cell line with high metastatic potential 
migrated strongest when directed by a FN gradient 
(Murata et al. 1992). In addition Lohi and co-
workers showed the ability of different RCC cell 
lines to secrete different FN isoforms (Lohi et al. 
1996). The inﬂ  uence of ECM components, espe-
cially FN, on renal tumor cell invasion was clearly 
demonstrated by Brenner and co-workers (Brenner 
et al. 2000). Wunderlich and co-workers described 
a positive correlation of oncofetal FN expression 
with prognostic parameters and concluded that 
high oncofetal FN may indicate poor outcome 
(Wunderlich et al. 2002). Our investigation 
supports this impression but we could not ﬁ  nd any 
correlation between cFN plasma levels and nuclear 
grading. 
In RCC, a malignancy missing a suitable marker 
so far, we found signiﬁ  cantly elevated plasma 
levels in patients suffering RCC compared to 
healthy controls. Additionally in metastatic stage 
of disease cFN levels are signiﬁ  cantly increasing 
pointing out the possible role of cFN in advanced 
RCC. In the face of higher plasma levels at the 
time of curative treatment cFN can play a role as 
follow-up tool. Furthermore in metastatic disease 
cFN can be helpful as control tool for response to 
therapy. These topics have to be evaluated in 
further investigations.
Additionally one cannot exclude the existence 
and detection of abnormal circulating FN isoforms 
in the different malignancies leading to different 
results; so all results have to be discussed carefully 
(Castellani et al. 1986).
In summary due to the relatively high standard 
deviation of it’s plasma concentrations cFN seems 
not to be a suitable marker for screening and 
detecting TCC and RCC. However, in the face of 
signiﬁ  cant elevated levels both in muscle invasive 
TCC and metastatic RCC cFN will be of high 
interest for monitoring patients during follow up 
after initial therapy: in TCC as a predictor of 
muscle invasive disease and in RCC as an indicator 
of recurrence and maybe to control response of 
therapy in metastatic stage of disease.
Our data on cFN as a marker of tumor progression 
for TCC and RCC encouraging further investigations 
with a larger number of patients before initial therapy 
and during follow-up to enlighten the future role of 
cFN for these urological malignancies.
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